Oncternal Therapeutics, Inc.

NasdaqCM:ONCT 株式レポート

時価総額:US$3.4m

Oncternal Therapeutics 過去の業績

過去 基準チェック /06

Oncternal Therapeuticsの収益は年間平均-10.7%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間19.1% 16.1%割合で 減少しています。

主要情報

-10.7%

収益成長率

60.0%

EPS成長率

Biotechs 業界の成長17.0%
収益成長率-16.1%
株主資本利益率-378.0%
ネット・マージン-1,600.0%
前回の決算情報30 Sep 2024

最近の業績更新

Recent updates

We Think Some Shareholders May Hesitate To Increase Oncternal Therapeutics, Inc.'s (NASDAQ:ONCT) CEO Compensation

Jun 14
We Think Some Shareholders May Hesitate To Increase Oncternal Therapeutics, Inc.'s (NASDAQ:ONCT) CEO Compensation

Can Oncternal Therapeutics (NASDAQ:ONCT) Afford To Invest In Growth?

Mar 03
Can Oncternal Therapeutics (NASDAQ:ONCT) Afford To Invest In Growth?

Here's Why We're A Bit Worried About Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation

Nov 06
Here's Why We're A Bit Worried About Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation

Oncternal Therapeutics (NASDAQ:ONCT) Will Have To Spend Its Cash Wisely

Jul 12
Oncternal Therapeutics (NASDAQ:ONCT) Will Have To Spend Its Cash Wisely

We're Keeping An Eye On Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate

Jan 12
We're Keeping An Eye On Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate

FDA clears Oncternal to proceed with dose escalation study for lymphoma car-T therapy

Oct 03

Oncternal Therapeutics begins phase 3 study of zilovertamab

Sep 27

Oncternal Therapeutics: Selling For Under Cash Value

Sep 02

Oncternal Therapeutics GAAP EPS of -$0.23 beats by $0.02, revenue of $0.2M misses by $0.26M

Aug 09

Here's Why We're Watching Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation

Aug 07
Here's Why We're Watching Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation

Oncternal to collaborate with an AbbVie company for its phase 3 lymphoma study

Jul 14

Oncternal Therapeutics: As Phase 2 Study Matures, Data Continues To Improve

Jun 07

We're Keeping An Eye On Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate

Apr 12
We're Keeping An Eye On Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate

Oncternal Therapeutics: Trading Near Cash With Impressive Results

Jan 04

Oncternal Therapeutics (NASDAQ:ONCT) Is In A Good Position To Deliver On Growth Plans

Nov 09
Oncternal Therapeutics (NASDAQ:ONCT) Is In A Good Position To Deliver On Growth Plans

Oncternal Therapeutics: Keep An Eye On This Biopharmaceutical Company

Oct 10

Oncternal: Solid Data In 2 Cancers With High Unmet Need

Jun 17

We Think Oncternal Therapeutics (NASDAQ:ONCT) Can Afford To Drive Business Growth

May 05
We Think Oncternal Therapeutics (NASDAQ:ONCT) Can Afford To Drive Business Growth

Should Oncternal Therapeutics (NASDAQ:ONCT) Be Disappointed With Their 81% Profit?

Mar 01
Should Oncternal Therapeutics (NASDAQ:ONCT) Be Disappointed With Their 81% Profit?

収支内訳

Oncternal Therapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NasdaqCM:ONCT 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
30 Sep 242-35120
30 Jun 242-3613-1
31 Mar 241-36130
31 Dec 231-39130
30 Sep 231-42130
30 Jun 231-43132
31 Mar 231-46130
31 Dec 221-44130
30 Sep 222-41130
30 Jun 224-39120
31 Mar 224-35120
31 Dec 214-31120
30 Sep 215-26100
30 Jun 214-21100
31 Mar 214-1890
31 Dec 203-1780
30 Sep 203-1990
30 Jun 202-19100
31 Mar 203-3790
31 Dec 192-3470
30 Sep 192-3150
30 Jun 192-2830
31 Mar 193-720
31 Dec 183-720
31 Dec 172-1030

質の高い収益: ONCTは現在利益が出ていません。

利益率の向上: ONCTは現在利益が出ていません。


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: ONCTは利益が出ておらず、過去 5 年間で損失は年間10.7%の割合で増加しています。

成長の加速: ONCTの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: ONCTは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 16.6% ) と比較することは困難です。


株主資本利益率

高いROE: ONCTは現在利益が出ていないため、自己資本利益率 ( -377.95% ) はマイナスです。


総資産利益率


使用総資本利益率


過去の好業績企業の発掘